Gene polymorphisms and prostate cancer: The evidence

BJU International

Volumn 104, Issue 11, 2009, Pages 1560-1572

  Dianat, Seyed S ^a   Margreiter, Markus ^a   Eckersberger, Elisabeth ^a   Finkelstein, Julia ^a   Kuehas, Franklin ^a   Herwig, Ralf ^a   Ayati, Mohsen ^a   Lepor, Herbert ^a   Djavan, Bob ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gene polymorphisms; Genome wide scan; Prostate; Prostatic neoplasms

Indexed keywords

ALPHA CATENIN; ANDROGEN; ANDROGEN RECEPTOR; ANTIBODY; BETA CATENIN; CYCLIN D1; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; JANUS KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLAKOGLOBIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VITAMIN D; VITAMIN D RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CHROMOSOME LOSS; DIET; DNA POLYMORPHISM; DNA REPAIR; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE ACTIVATION; GENE CONTROL; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HORMONE RECEPTOR INTERACTION; HUMAN; MEDLINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CELL ADHESION; GENES, CDC; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 70449353827     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08973.x     Document Type: Short Survey

References (131)

1. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009 73 : S4 10
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009 59 : 225 249
3. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994 152 : 1484 1489
4. Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol 1999 35 : 362 369 (Pubitemid 29229534)
5. Brinkmann AO, Faber PW, van Rooij HC et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem 1989 34 : 307 310
6. Kuiper GG, Faber PW, van Rooij HC et al. Structural organization of the human androgen receptor gene. J Mol Endocrinol 1989 2 : R1 4
7. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG) n-expanded neuronopathies. Hum Mol Genet 1995 4 : 523 527
8. Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor. J Natl Cancer Inst 1994 86 : 872 873
9. Mononen N, Schleutker J. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol 2009 181 : 1541 1549
10. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 2004 13 : 1765 1771
11. Lindstrom S, Zheng SL, Wiklund F et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006 66 : 1729 1743
12. Freedman ML, Pearce CL, Penney KL et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 2005 76 : 82 90
13. Lange EM, Sarma AV, Ray A et al. The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: Results from the Flint Men's Health Study. J Hum Genet 2008 53 : 220 226
14. Chang BL, Zheng SL, Hawkins GA et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 2002 110 : 122 129
15. Lindstrom S, Wiklund F, Adami HO, Balter KA, Adolfsson J, Gronberg H. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res 2006 66 : 11077 11083
16. Mittal RD, Mishra DK, Thangaraj K, Singh R, Mandhani A. Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population? Steroids 2007 72 : 335 341
17. Sieh W, Edwards KL, Fitzpatrick AL et al. Genetic susceptibility to prostate cancer: prostate-specific antigen and its interaction with the androgen receptor (United States). Cancer Causes Control 2006 17 : 187 197
18. Powell IJ, Land SJ, Dey J et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 2005 103 : 528 537
19. Nam RK, Elhaji Y, Krahn MD et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000 164 : 567 572
20. Stanford JL, Just JJ, Gibbs M et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997 57 : 1194 1198
21. Platz EA, Leitzmann MF, Rifai N et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005 14 : 1262 1269
22. Kibel AS, Isaacs WB. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology 2000 55 : 316 322
23. Tomlins SA, Mehra R, Rhodes DR et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007 39 : 41 51
24. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000 14 : 2410 2434
25. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996 274 : 1664 1672
26. van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 2007 61 : 104 139
27. Jarrard DF, Bova GS, Ewing CM et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997 19 : 90 6
28. Heidenreich B, Heidenreich A, Sesterhenn A, Srivastava S, Moul JW, Sesterhenn IA. Aneuploidy of chromosome 9 and the tumor suppressor genes p16 (INK4) and p15 (INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 2000 38 : 475 482
29. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer. Int J Cancer 1999 83 : 610 614
30. Park DJ, Wilczynski SP, Pham EY, Miller CW, Koeffler HP. Molecular analysis of the INK4 family of genes in prostate carcinomas. J Urol 1997 157 : 1995 1999
31. Gu K, Mes-Masson AM, Gauthier J, Saad F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol Carcinog 1998 21 : 164 170
32. Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA, Akslen LA. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000 88 : 416 424
33. Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998 58 : 5652 5655
34. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27 (Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997 3 : 2269 2274
35. Cote RJ, Shi Y, Groshen S et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998 90 : 916 920
36. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000 6 : 1891 1895
37. Gumbiner LM, Gumerlock PH, Mack PC et al. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 1999 38 : 40 5
38. Wang L, Habuchi T, Takahashi T et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002 23 : 257 264 (Pubitemid 34224000)
39. Chang BL, Zheng SL, Isaacs SD et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004 64 : 1997 1999
40. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001 49 : 263 266
41. Kibel AS, Suarez BK, Belani J et al. CDKN 1A, CDKN 1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003 63 : 2033 2036
42. Koike H, Suzuki K, Satoh T et al. Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res 2003 23 : 4947 4951
43. Suzuki K, Matsui H, Ohtake N et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003 10 : 430 435
44. Wang L, Habuchi T, Mitsumori K et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003 103 : 116 120
45. Kibel AS, Jin CH, Klim A et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008 68 : 1179 1186
46. Hirata H, Hinoda Y, Kikuno N et al. Bcl2-938C/A. polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009 181 : 1907 1912
47. Umbas R, Isaacs WB, Bringuier PP et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994 54 : 3929 3933
48. Dunsmuir WD, Gillett CE, Meyer LC et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000 86 : 869 878
49. Suzuki H, Komiya A, Emi M et al. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996 17 : 225 233
50. Li LC, Chui RM, Sasaki M et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000 60 : 873 876
51. Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 2002 100 : 683 685
52. Jonsson BA, Adami HO, Hagglund M et al. -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004 109 : 348 352
53. Tsukino H, Kuroda Y, Imai H et al. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int 2004 72 : 203 207
54. Kamoto T, Isogawa Y, Shimizu Y et al. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn J Clin Oncol 2005 35 : 158 161
55. Goto T, Nakano M, Ito S, Ehara H, Yamamoto N, Deguchi T. Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population. Urology 2007 70 : 127 130
56. Bonilla C, Mason T, Long L et al. E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate 2006 66 : 546 556
57. Pookot D, Li LC, Tabatabai ZL, Tanaka Y, Greene KL, Dahiya R. The E-cadherin-160C/A polymorphism and prostate cancer risk in white and black American men. J Urol 2006 176 : 793 796
58. Qiu LX, Li RT, Zhang JB et al. The E-cadherin (CDH1) -160C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet 2009 17 : 244 249
59. Paffenholz R, Franke WW. Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family. Differentiation 1997 61 : 293 304
60. Paffenholz R, Kuhn C, Grund C, Stehr S, Franke WW. The arm-repeat protein NPRAP (neurojungin) is a constituent of the plaques of the outer limiting zone in the retina, defining a novel type of adhering junction. Exp Cell Res 1999 250 : 452 464
61. Lu Q, Paredes M, Medina M et al. δ-catenin, an adhesive junction-associated protein which promotes cell scattering. J Cell Biol 1999 144 : 519 532
62. Wang T, Chen YH, Hong H et al. Increased nucleotide polymorphic changes in the 5′-untranslated region of delta-catenin (CTNND2) gene in prostate cancer. Oncogene 2009 28 : 555 564
63. Burger MJ, Tebay MA, Keith PA et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 2002 100 : 228 237
64. Lu Q, Dobbs LJ, Gregory CW et al. Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol 2005 36 : 1037 1048
65. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998 58 : 2520 2523
66. Arandi N, Talei A, Erfani N, Ghaderi A. Intercellular adhesion molecule-1 genetic markers (+241G/A and +469A/G) in Iranian women with breast cancer. Cancer Genet Cytogenet 2008 183 : 9 13
67. Vinceti M, Pellacani G, Casali B et al. High risk of cutaneous melanoma amongst carriers of the intercellular adhesion molecule-1, R241 allele. Melanoma Res 2006 16 : 93 6
68. Chen H, Hernandez W, Shriver MD, Ahaghotu CA, Kittles RA. ICAM gene cluster SNPs and prostate cancer risk in African Americans. Hum Genet 2006 120 : 69 76
69. Shirai A, Furukawa M, Yoshizaki T. Expression of intercellular adhesion molecule (ICAM)-1 in adenoid cystic carcinoma of the head and neck. Laryngoscope 2003 113 : 1955 1960
70. Tachimori A, Yamada N, Sakate Y et al. Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma. Eur J Cancer 2005 41 : 1802 1810
71. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 : 353 364
72. McCarron SL, Edwards S, Evans PR et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002 62 : 3369 3372
73. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006 35 : 21 8
74. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 2003 62 : 374 377
75. Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position-460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep 2008 35 : 17 22
76. Fukuda H, Tsuchiya N, Narita S et al. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep 2007 18 : 1155 1163
77. Langsenlehner T, Langsenlehner U, Renner W et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer 2008 44 : 1572 1576
78. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998 19 : 711 721 (Pubitemid 28376759)
79. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007 27 : 317 352
80. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci USA 2001 98 : 8638 8643
81. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000 36 : 1649 1660
82. Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003 36 : 120 127
83. Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H. Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett 2005 217 : 197 202
84. Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R. Vascular invasion in human breast cancer is correlated to T - >786C polymorphism of NOS3 gene. Nitric Oxide 2003 9 : 118 122
85. Medeiros RM, Morais A, Vasconcelos A et al. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 2002 8 : 3433 3437 (Pubitemid 35340718)
86. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998 82 : 1897 1903
87. Marangoni K, Araujo TG, Neves AF, Goulart LR. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. BMC Cancer 2008 8 : 273
88. Lee KM, Kang D, Park SK et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009 30 : 621 625
89. Teixeira AL, Ribeiro R, Cardoso D et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 2008 14 : 3367 3371
90. Tuohimaa P, Tenkanen L, Ahonen M et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004 108 : 104 108
91. Ahn J, Peters U, Albanes D et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008 100 : 796 804
92. Travis RC, Crowe FL, Allen NE et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 2009 169 : 1223 1232
93. Konety BR, Getzenberg RH. Vitamin D and prostate cancer. Urol Clin North Am 2002 29 : 95 106, ix
94. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006 175 : 1613 1623
95. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996 56 : 4108 4110
96. Ingles SA, Ross RK, Yu MC et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997 89 : 166 170
97. Maistro S, Snitcovsky I, Sarkis AS, da Silva IA, Brentani MM. Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men. Int J Biol Markers 2004 19 : 245 249
98. Cheteri MB, Stanford JL, Friedrichsen DM et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004 59 : 409 418
99. Huang SP, Chou YH, Wayne Chang WS et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004 207 : 69 77
100. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009 18 : 1929 1933
101. Torkko KC, van Bokhoven A, Mai P et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 2008 14 : 3223 3229
102. Habuchi T, Suzuki T, Sasaki R et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000 60 : 305 308 (Pubitemid 30070756)
103. Suzuki K, Matsui H, Ohtake N et al. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 2003 10 : 261 266 (Pubitemid 36609464)
104. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007 16 : 1990 1999
105. Williams H, Powell IJ, Land SJ et al. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate 2004 61 : 267 275
106. Mishra DK, Bid HK, Srivastava DS, Mandhani A, Mittal RD. Association of vitamin D receptor gene polymorphism and risk of prostate cancer in India. Urol Int 2005 74 : 315 318
107. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004 1 : R103 21
108. Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996 274 : 1371 1374
109. Berthon P, Valeri A, Cohen-Akenine A et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998 62 : 1416 1424
110. Berry R, Schaid DJ, Smith JR et al. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000 66 : 539 546
111. Eeles RA, Durocher F, Edwards S et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 1998 62 : 653 658
112. Cooney KA, McCarthy JD, Lange E et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997 89 : 955 959
113. Gronberg H, Smith J, Emanuelsson M et al. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet 1999 65 : 134 140
114. Nam RK, Zhang WW, Loblaw DA et al. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Cancer Prostatic Dis 2008 11 : 241 246
115. Suarez BK, Lin J, Burmester JK et al. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 2000 66 : 933 944
116. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001 68 : 1197 1206
117. Sun J, Lange EM, Isaacs SD et al. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate 2008 68 : 489 497
118. Wang L, McDonnell SK, Slusser JP et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007 67 : 2944 2950
119. FitzGerald LM, Patterson B, Thomson R et al. Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet 2009 17 : 368 377
120. Camp NJ, Farnham JM, Wong J, Christensen GB, Thomas A, Cannon-Albright LA. Replication of the 10q11 and Xp11 prostate cancer risk variants: Results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev 2009 18 : 1290 1294
121. Terada N, Tsuchiya N, Ma Z et al. Association of genetic polymorphisms at 8q24 with the risk of prostate cancer in a Japanese population. Prostate 2008 68 : 1689 1695
122. Lange EM, Beebe-Dimmer JL, Ray AM et al. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate 2009 69 : 385 391
123. Chau CH, Permenter MG, Steinberg SM et al. Polymorphism in the hypoxia-inducible factor 1α gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005 4 : 1222 1225
124. Foley R, Marignol L, Thomas AZ et al. The HIF-1α C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther 2009 8 : 118 124
125. Jacobs EJ, Hsing AW, Bain EB et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 2008 17 : 972 977
126. Wu HC, Lai MT, Wu CI et al. E-cadherin gene 3′-UTR C/T polymorphism is associated with prostate cancer. Urol Int 2005 75 : 350 353
127. Lockett KL, Hall MC, Xu J et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004 64 : 6344 6348
128. Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol 2006 175 : 108 112
129. Angele S, Falconer A, Edwards SM et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 2004 91 : 783 787
130. Xu J, Zheng SL, Turner A et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 2002 62 : 2253 2257 (Pubitemid 34411700)
131. Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 2003 170 : 2471 2474